Summary To obtain suitable cell lines for the immortalisation of human lymphocytes, we constructed a heteromyeloma between the murine myeloma Ag8 and human lymphocytes from a highly malignant polymorphic, centroblastic B-cell lymphoma. The thioguanine-resistant and HAT-sensitive heteromyeloma HAB-1 neither secretes nor contains cytoplasmatic immunoglobulins, the cells being EBV negative but positively stained for HLA-BC and the human proliferation marker (Foung et al., 1984; Yamaura et al., 1985; Teng et al., 1985; Ichimori et al., 1985; Caroll et al., 1986; Martin et al., 1988; Grunow et al., 1988; Vollmers et al., 1989) . Some of the heteromyeloma products were stable for 6 months or longer without intensive recloning procedures, but only few of these fusion partners are available. We describe in this paper a new genetically stable human-mouse heteromyeloma, HAB-1, which was produced by somatic hybridisation of murine Ag8 myeloma cells with human lymphocytes from a patient with a B-cell lymphoma. The cell line has ideal growth and fusion characteristics and has been successfully used for the long-term production of human monoclonal antibodies against stomach carcinoma cells.
For the production of human monoclonal antibodies several experimental systems have been used to immortalise human B-cells Human -mouse hybrids are genetically unstable, resulting in a rapid loss of antibody production (Croce et al., 1980; Cote et al., 1983; Gigliotti et al., 1984; ) . Several experiments have been performed with human myeloma and lymphoblastoid cells (Olsson & Kaplan, 1980; Abrams et al., 1983; Ritts et al., 1983; Satoh et al., 1983; Strike et al., 1984; Glassy et al., 1983; Borrebaek et al., 1987) , but there is still a need for suitable malignant lines. Transformation of human lymphocytes by EBV or somatic hybridisation of EBV-transformed lymphocytes with myeloid cells is still the most commonly used method for immortalising human lymphocytes (Kozbor & Roder, 1981; Cote et at., 1984; Yamaguchi et al., 1987; Furukawa et al., 1988) . The major disadvantage of this technique is the possible contamination of hybridoma supernatants with viral products.
The most promising approach to obtain stable human monoclonal antibodies producing B-lymphocytes was originally described by Teng et al. (1983) . The authors constructed a heteromyeloma between a human lymphoblastoid cell line (FU 266) and a murine myeloma (Ag8) and isolated a non-secreting, TG-resistant and HAT-sensitive cell line PSV2.Neo. These cells gave greater numbers of stable hybrids when fused with lymphocytes than did mouse cells alone. Ostberg and Pursch (1983) produced a heteromyeloma fusion partner from the mouse myeloma line SP2/0 and normal human peripheral blood lymphocytes (PBLs). They fused this heteromyeloma with lymphocytes from immunised donors and established hybridomas which showed stable antibody production in long-term and mass culture. Several other laboratories have used such heteromyelomas between murine myelomas and human myelomas, normal human Blymphocytes or B-lymphoma cells for production of human antibodies (Foung et al., 1984; Yamaura et al., 1985; Teng et al., 1985; Ichimori et al., 1985; Caroll et al., 1986; Martin et al., 1988; Grunow et al., 1988; Vollmers et al., 1989) . Some of the heteromyeloma products were stable for 6 months or longer without intensive recloning procedures, but only few of these fusion partners are available. We describe in this paper a new genetically stable human-mouse heteromyeloma, HAB-1, which was produced by somatic hybridisation of murine Ag8 myeloma cells with human lymphocytes from a patient with a B-cell lymphoma. The cell line has ideal growth and fusion characteristics and has been successfully used for the long-term production of human monoclonal antibodies against stomach carcinoma cells.
Materials and methods

Cells and culture conditions
The non-secreting HAT (hypoxanthine-aminopterinthymidine) sensitive heteromyeloma HAB-1 derived from hybridisation of murine Ag8 myeloma cells with lymph node cells from a patient with a highly malignant centroblastic B-cell lymphoma. Selected hybrids were exposed once to 6-thioguanine (5 lAg ml-') and growing clones were tested for HAT-sensitivity. Established TG. Several TG-mutants could be isolated and were subsequently tested for HAT-sensitivity. The Ig-negative and HAT-sensitive heteromyeloma HAB-1 was selected for further investigations for mainly two reasons: the cells die after a relatively short time in HAT-medium (after 3-4 days, data not shown) and show a rapid proliferation in normal culture medium. The cells grow in solution, double every 25-30 h and reach a maximal density of about 2 x 106 cells ml- (Figure 1 ). By using immunohistochemical staining procedures the phenotype of HAB-1 was determined and compared with the primary B-lymphoma 10030, used for construction of HAB-1 and a HAB-1 heteromyeloma fusion product, 70/5 (IgA, k). Table I shows that the heterogeneous lymphoma cell population is positively stained for T-cells (CD3), T-subsets (CD4, CD5) and NK-cells (CD57). When tested for B-cell markers, Compared to this the heteromyeloma HAB-1 is only positive for HLA-BC and Ki-67, while all other markers are lost. The HAB-1 fusion product 70/5, which secretes an IgA (k), has the same characteristics. From these data, one cannot determine from which type of cell, lymphoma cell or proliferating normal lymphocyte, the heteromyeloma derived.
To investigate the karyotype of the heteromyeloma HAB-1 G-banding experiments were performed. Figure 2a shows that the Ag8 cells have on average 50 acrocentric and two metacentric chromosomes, whereas HAB-1 has around 65 -70 chromosomes (Figure 2b ). Consistently, in most metaphases, followed over a longer period of time in culture, chromosomes 6; 13, 14, 15; 16, 17, 18 and 21, 22 are always retained in the heteromyeloma (Figure 2c) . No significant change in the number of human chromosomes could be observed after one year of cultivation.
In freshly re-cloned HAB-1 fusion products 25-30 human chromosomes can be identified and after 12 months in culture there are still around 20 (not shown).
Somatic hybridisations with the heteromyeloma HAB-J To investigate the fusion characteristics of the heteromyeloma HAB-1, several hybridisations were done with spleen cells from stomach carcinoma patients and the HAB-l is 5-7 times higher than that obtained with SPM4-0 or Ag8. The number of Ig-producing clones is similar with all three fusion partners, i.e. between 20 and 26%.
To determine the stability of the fusion products, the primary cells were re-cloned once and the supernatants of the reclones were tested every two weeks for antibody production. The hybrids generated with Ag8 usually lose antibody activity after 2 months, whereas the heteromyeloma products show a much longer stability, some having been in culture now for more than 2 years. Using HAB-l as fusion partner, several human monoclonal antibodies which react with the autologous tumour cells could be isolated from stomach carcinoma patients. As an example, Figure 3a shows a fluorescence staining with the antibody 94/51 (IgM) on cultured stomach adenocarcinoma cells.
Discussion
Rapid proliferation and genetic stability of fusion partners and products is most important for successful long-term production of human monoclonal antibodies. We described in a recent study the establishment of human monoclonal antibodies from patients with signet ring carcinomas of the stomach by using the heteromyeloma SPM4-0 as source of parental cells (Vollmers et al., 1989 (1986) , who made heteromyelomas between NS-1 cells and lymphoid cells from a patient with a nodular lymphoma. They obtained heteromyelomas with excellent fusion and growth characteristics, but the fusion products showed only a low stability (<2 months), most likely due to genetic instability. The stability of a heteromyeloma is surely influenced by the number of human chromosomes in the parental heteromyeloma. Grunow et al. (1988) described a heteromyeloma named CB-F7 with good growth and fusion characteristics. Chromosomal analysis of this cell line revealed around 70 murine and only three human chromosomes. In hybridomas between CB-F7 and human PBLs only 5-10 human chromosomes were observed. The hybrids showed stable Ig-production up to 6 months under normal growth conditions, but for long-term cultures the cells had to be re-cloned 2-4 times.
The heteromyeloma HAB-1 was therefore selected for its high proliferation rate and high number and low segregation of human chromosomes in the parental cell over a long period of time. G-banding experiments with HAB-1 revealed about 15-20 huan chromosomes, which are still found after 1 year in cell culture. A preferential retention was found for chromosomes 6, 11, 13, 14, 15, 16, 17, 18, 21 and 22 . No significant change in the karyotype could be observed after 1 year of cultivation. Cytogenetic studies with HAB-1 fusion products gave similar results. Freshly re-cloned cells had about 75-85 chromosomes (50 mouse and 25-35 human) and still around 70 chromosomes even after 1 year in culture.
The described characteristics together with the facts that HAB-1 is negative for EBV and does not produce and secrete its own immunoglobulins make the cells an ideal fusion partner for human lymphocytes.
